Exact Sciences supplies the Oncotype DX breast cancer test to NHS Wales
- NHS Wales Shared Services Partnership
- Wales
- Open, 1 bid
- 1 June 2026 to 1 June 2029
NHS Wales Shared Services Partnership has contracted Exact Sciences to supply the Oncotype DX Breast Recurrence Score Test for cancer services.
The test gives a genomic risk score for early-stage invasive breast cancer, which helps doctors judge whether chemotherapy would help or hormone therapy alone will do. NICE has recommended it for node-negative cases.
The company was the only bidder in an open tender. Its contract, estimated at £275,400, was awarded in June 2026 and can run to June 2030 with an extension of up to 12 months.
Contract ends June 2029
- What
- Pathology and specialist laboratory testing services
- Supplier
- Exact Sciences
- Value
- £275,400
- How it was bought
- Open
- 1 bid
- Dates and next
- Jun 2026 to Jun 2029
- Option to Jun 2030